AR and neoplasm: The observation that androgen production by the adrenal glands or by the tumor itself is still able to fuel proliferation led to the development and approval of androgen receptor (AR)-targeted therapies with pharmaceutical drugs such as enzalutamide, apalutamide or darolutamide, which turn off AR function, or abiraterone, which inhibits the CYP17,20 lyase involved in androgen synthesis [2,3,4,5].